Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged at risk
Is Boehringer Ingelheim planning to launch its Humira biosimilar at-risk?

Boehringer Ingelheim has been one of the lone holdouts in AbbVie’s ($ABBV) campaign to delay biosimilar competition against Humira® until 2023.  To date, AbbVie has settled with almost all proposed biosimilars for entry dates in 2023.  Is Boehringer going to launch at-risk?

Read More
Markman AdvisorsAbbVie, $ABBV, Boehringer-Ingelheim, Amgen, FDA, biosimilar, Humira, patent, Inter Partes Review, IPR, patent thicket, thicket, Cyltezo, at-risk launch, at risk, Zachary Silbersher, SilbersherComment